Rallybio Corp
Rallybio Corp has a market capitalization of $75.17 million and a price-to-book ratio of 0.84, indicating that the company is trading at a discount relative to its book value. The company's liquidity position is strong, with a current ratio of 9.77, suggesting that it has sufficient current assets to cover its current liabilities multiple times over. However, the company has no long-term debt, which may limit its ability to leverage its balance sheet for growth opportunities. The company's profitability metrics are negative, with a return on equity of -21.34% and a return on assets of -19.15%, indicating that it is not generating returns for its shareholders or effectively utilizing its assets. The operating income and net income are both negative, at -$20.47 million and -$19.03 million, respectively, which is below the industry median for biotechnology companies. The company's EBITDA multiple is negative at -2.73, further highlighting its unprofitable operations. Rallybio Corp's revenue is not disclosed in the provided data, but the company's operations are concentrated in the biotechnology and medical research industry. The company's geographic exposure is not specified, but it is likely focused on the United States given its listing on the NASDAQ. The company's revenue concentration in a single industry may expose it to sector-specific risks, such as regulatory changes or shifts in research funding. The company's growth trajectory is uncertain, with no specific revenue growth projections provided. The company's operating cash flow and free cash flow are both negative, at -$15.46 million and -$18.99 million, respectively, indicating that it is not generating positive cash flow from operations. The company's negative earnings per share (EPS) of -$1.59 and a mean EPS estimate of -$4.60 suggest that it is not expected to become profitable in the near term. The company's risk profile is characterized by low liquidity and dilution risk, with no immediate filing-based flags detected. The company has a low dilution potential, with no significant dilution sources identified in the provided data. The company's financial structure is relatively simple, with no long-term debt and a low debt-to-equity ratio of 0.0. Recent events related to Rallybio Corp include analyst estimates that suggest a neutral outlook, with one "hold" recommendation and no strong buy or sell recommendations. The company's financial performance has been consistently negative, with no signs of improvement in the near term. The company's management and board of directors have not disclosed any significant strategic initiatives or partnerships that could drive future growth.
Business. Rallybio Corp is a biotechnology company focused on developing and commercializing novel therapeutics for patients with rare and serious diseases.
Classification. Rallybio Corp is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, and the Biotechnology & Medical Research industry, with a classification confidence of 0.92.
- Rallybio Corp is a biotechnology company with a strong liquidity position but negative profitability metrics.
- The company's market capitalization is $75.17 million, and it is trading at a price-to-book ratio of 0.84.
- Rallybio Corp has a current ratio of 9.77, indicating a strong ability to meet short-term obligations.
- The company's return on equity and return on assets are both negative, at -21.34% and -19.15%, respectively.
- Rallybio Corp has no long-term debt, which may limit its ability to leverage its balance sheet for growth.
- The company's financial performance is expected to remain negative, with a mean EPS estimate of -$4.60.
- ## RATIONALES
- **margin_outlook_rationale**: Rallybio Corp's margin outlook is negative due to its consistent negative operating and net income, which is below the industry median for biotechnology companies.
- No immediate filing-based liquidity or dilution flags were detected.